Start Date
4-16-2024 3:45 PM
End Date
4-16-2024 4:45 PM
Description
Abstract
The Chimeric Antigen Receptor T-cells, also known as CAR T-cells, are a revolutionary approach to cancer treatment. They are engineered Tlymphocytes and recombinant receptors for specific antigens. They are mainly responsible for redirecting specificity, activation, and function of T lymphocytes and other immune cells in a single molecule. It attaches to the cancer cells, thereby leading to the destruction of the tumor. The CAR Tcells are made up of different domains, which include Antigen Binding Domain (CD19), Hinge, and Transmembrane Region, followed by Co- Stimulatory Domain (CD28) and T-cell Activation Domain (CD3). The Antigen Binding Domain recognizes the specific target of cancer cells. The Hinge and Transmembrane Region is responsible for the CAR signaling threshold and the amount of CAR signaling by controlling the CAR expression level. The T-cell Activation Domain regulates the activation of Tcells, whereas the Co-stimulatory Domain plays a role in giving secondary signals for T-cell activation. The designing of CAR T-cells involves various steps, which include a collection of the patient’s blood, followed by isolation of T-cells from it, activation/stimulation of patient’s T-cells using CD3/CD28 activation beads, along with the addition of interleukin 2, which is used to enhance the efficiency of T-cell stimulation. Then, the T-cells are genetically modified with CAR complex, thereby forming CAR T-cells, which are then expanded in the laboratory and infused back into the patient’s body to fight against leukemia.
Included in
Engineered CAR19 T-cells to Demonstrate in vitro Antileukemia Activity
Abstract
The Chimeric Antigen Receptor T-cells, also known as CAR T-cells, are a revolutionary approach to cancer treatment. They are engineered Tlymphocytes and recombinant receptors for specific antigens. They are mainly responsible for redirecting specificity, activation, and function of T lymphocytes and other immune cells in a single molecule. It attaches to the cancer cells, thereby leading to the destruction of the tumor. The CAR Tcells are made up of different domains, which include Antigen Binding Domain (CD19), Hinge, and Transmembrane Region, followed by Co- Stimulatory Domain (CD28) and T-cell Activation Domain (CD3). The Antigen Binding Domain recognizes the specific target of cancer cells. The Hinge and Transmembrane Region is responsible for the CAR signaling threshold and the amount of CAR signaling by controlling the CAR expression level. The T-cell Activation Domain regulates the activation of Tcells, whereas the Co-stimulatory Domain plays a role in giving secondary signals for T-cell activation. The designing of CAR T-cells involves various steps, which include a collection of the patient’s blood, followed by isolation of T-cells from it, activation/stimulation of patient’s T-cells using CD3/CD28 activation beads, along with the addition of interleukin 2, which is used to enhance the efficiency of T-cell stimulation. Then, the T-cells are genetically modified with CAR complex, thereby forming CAR T-cells, which are then expanded in the laboratory and infused back into the patient’s body to fight against leukemia.
